Skeletal muscle is a major insulin target tissue and has a prominent role in the control of body amino acid economy, being the principal store of free and protein-bound amino acids and a dominant locus for amino acid metabolism. Interplay between diverse stimuli (e.g., hormonal/nutritional/mechanical) modulates muscle insulin action to serve physiological need through the action of factors such as intramuscular signaling molecules. Ceramide, a product of sphingolipid metabolism and cytokine signaling, has a potent contra-insulin action with respect to the transport and deposition of glucose in skeletal muscle, although ceramide effects on muscle amino acid turnover have not previously been documented. Here, membrane permeant C 2 -ceramide is shown to attenuate the basal and insulin-stimulated activity of the Na + -dependent System A amino acid transporter in rat muscle cells (L6 myotubes) by depletion of the plasma membrane abundance of SNAT2 (a System A isoform). Concomitant with transporter downregulation, ceramide diminished both intramyocellular amino acid abundance and the phosphorylation of translation regulators lying downstream of mTOR. The physiological outcome of ceramide signaling in this instance is a marked reduction in cellular protein synthesis, a result that is likely to represent an important component of the processes leading to muscle wasting in catabolic conditions. Key words: insulin • rapamycin • SNAT2 • Me-AIB • PKB/Akt keletal muscle contains the largest pool of free amino acids in the body (reviewed in refs 1 and 2). This pool is dynamically controlled during physiological and pathophysiological circumstances by the coordinated regulation of amino acid transport, amino acid metabolism, protein synthesis, and proteolysis. For example, such regulation allows skeletal muscle to function both as a source of gluconeogenic amino acids during periods of catabolic stress and as a postprandial amino acid sink. Dysregulation of skeletal muscle amino acid balance may contribute to pathological conditions associated with diseases such as diabetes mellitus and cancer (3-5), since muscle wasting can occur concomitant with the depletion of muscle amino acids.
amino acid transport in mammalian cells (reviewed in refs 6 and 7). SNAT2 transports shortchain neutral amino acids in symport with sodium ions with a 1:1 stoichiometry (8-10) and utilizes the Na + electrochemical gradient to concentrate amino acids into the cytosol. Amino acids accumulated in this manner may be used for protein synthesis, metabolism, or to provide a driving force for the transmembrane transport of other amino acids by amino acid exchangers (7) .
Transport via SNAT2 is subject to tight regulatory control at both the transcriptional and posttranslational level. The expression of SNAT2 is increased following amino acid deprivation, hyperosmotic stress, experimental diabetes, and treatment with cyclic AMP agonists in a celland/or tissue-specific manner (reviewed in ref 6) . Furthermore, our group has shown that insulin may stimulate the translocation of SNAT2 from an endosomal location to the plasma membrane in L6 myotubes, a mechanism proposed to account for the increase in System A activity observed in these cells following acute insulin treatment (11) . Subcellular redistribution events have also been proposed to play a role in the up-regulation of SNAT2 activity following amino acid deprivation (12) and partial hepatectomy (13) .
Elevated dietary saturated fat may impair insulin action in primary target tissues (skeletal muscle, adipose, liver; reviewed in refs [14] [15] [16] . The sphingosine derivative ceramide is a putative mediator of the progression of insulin target tissues to an insulin-resistant phenotype, particularly in response to saturated fat intake (17) (18) (19) (20) . There is also evidence that intramuscular ceramide levels are raised during starvation (21) , in genetically obese rats (22) and following denervation (22) -situations within which insulin action is impaired. Furthermore, ceramide levels are reduced in rat skeletal muscle following prolonged exercise (23) and are negatively correlated with muscle glucose transport (20) . Since ceramide is synthesized from saturated fat and ceramide synthesis may be stimulated by adipocyte-derived cytokines (including tumor necrosis factor α [TNF-α]; 24), the intramuscular accumulation of this lipid may correlate with systemic obesity. Intriguingly, supplementation studies have reproducibly demonstrated that ceramide (either given directly in the form of cell-permeable analogs, or indirectly by synthesis from intracellular saturated fatty acids or TNF-α treatment) can impair insulin signaling to key downstream responses, such as the stimulation of glucose transport and glycogen synthesis in muscle and adipose tissue (17) (18) (19) (25) (26) (27) (28) . Surprisingly, given the dominant role of skeletal muscle in the regulation of whole body amino acid economy, the effects of ceramide on muscle amino acid balance and protein metabolism have not previously been documented.
In this report, we demonstrate that the provision of a cell-permeable ceramide to L6 myotubes results in a time-and dose-dependent inhibition of System A activity and also renders System A activity insensitive to insulin. This effect was mimicked by palmitate, a physiological substrate for de novo ceramide synthesis. Subcellular fractionation studies demonstrate that the inhibitory effect of ceramide occurs through the relocalization of the SNAT2 transporter away from the plasma membrane. These effects appear to utilize signaling pathways distinct from those involved in the regulation of glucose transport by insulin and ceramide. Ceramide treatment reduced the intracellular concentration of both System A and non-System A amino acid substrates within the cell, suggestive of an important role for SNAT2 in the maintenance of transmembrane amino acid gradients in skeletal muscle. Furthermore, ceramide inhibited the rate of cellular protein synthesis and diminished signaling through the mTOR pathway.
MATERIALS AND METHODS

Materials
Culture media (α-minimal essential medium, α-MEM), fetal calf serum, and antimycotic/antibiotic solution were from Invitrogen (Renfrewshire, UK). Palmitate, palmitoleate, and reagent-grade chemicals were from Sigma-Aldrich (Poole, UK). C 2 -ceramide was from Tocris (Bristol, UK). C 2 -dihydroceramide and okadaic acid were from CalbiochemNovabiochem (Nottingham, UK). Radiochemicals were from PerkinElmer Life Sciences (Cambridge, UK).
Cell culture
L6 rat skeletal muscle cells were cultured to the stage of myotubes (11, 29) in α-MEM containing 2% (v/v) fetal calf serum and antimycotic/antibiotic solution (100 U/ml penicillin, 100 µg/ml streptomycin, and 250 ng/ml amphotericin B) at 37°C in an atmosphere of 5% CO 2 /95% air. Following differentiation, cells were incubated in serum-free α-MEM for 5 h. Additions (e.g., insulin, ceramide) to the cells were made as indicated in figure legends. In certain experiments, L6 cells were serum starved in Earl's balanced salt solution (EBSS) supplemented with an amino acid mix at physiological concentration (29) for 3 h and were subsequently incubated in EBSS either containing or lacking amino acids for 2 h.
Subcellular fractionation of L6 skeletal myotubes
Subcellular membranes from L6 myotubes were isolated as described previously (11, 29) . Following ceramide treatment, cells from five (15 cm) dishes were harvested, pooled, and gently pelleted. The cell pellet was homogenized (250 mM sucrose, 20 mM HEPES, 5 mM NaN 3 , 2 mM EGTA, pH 7.4, plus 1 protease inhibitor tablet/50 ml) and subjected to a series of differential centrifugation steps to isolate crude cell membranes that were subsequently fractionated on a discontinuous sucrose gradient (32, 40, and 50% sucrose by mass) at 210,000 g for 2.5 h. Membranes from on top of the 32% sucrose cushion and those at the 32/40% and 40/50% sucrose interfaces were recovered and their protein content determined using the Bradford assay (30).
SDS-PAGE and immunoblotting
Cell membranes (20 µg protein) or lysates (50 µg) were subjected to SDS-PAGE and immunoblotting as described previously (11, 29) . Separated proteins were transferred onto Immobilon P membrane (Millipore, Bedford, MA) and blocked with Tris-buffered saline (pH 7.4) containing 5% (w/v) milk protein and 0.05% (v/v) Tween-20. Membranes were probed with phospho-specific antibodies against TSC2 (a gift from Prof. D. Alessi, University of Dundee), S6 (Upstate, Dundee, UK), or various other signaling molecules (New England BioLabs, Hitchin, UK) or with polyclonal antibodies against the SNAT2 System A transporter (1:3000 v/v) (29), actin (Sigma-Aldrich, Poole, UK), or a monoclonal antibody against the α1 subunit of the Na 
Measurement of solute transport activities
Transport activities were determined as described previously (11, 31 ]-2-deoxyglucose (2-DG) for 10 min (each at 47.6 kBq/ml). Nonspecific tracer binding was quantified by determining cell-associated radioactivity in the presence of a saturating dose of unlabeled Me-AIB, leucine or alanine (each at 10 mM), or in the presence of 10 µM cytochalasin B. Cells were washed three times with isotonic saline (0.9% NaCl, w/v) to terminate uptake activity and were lysed in 50 mM NaOH. Cell-associated radioactivity was determined by liquid scintillation counting and standardized to protein recovery.
Analysis of intracellular amino acid composition
L6 cells were grown on 3.5 cm plates and treated with ceramide as described above. Following experimental treatments, myotubes were washed twice with ice-cold phosphate buffered saline (PBS) and scraped into 300 mM perchloric acid. The suspension was centrifuged (3000 g, 10 min), and the supernatant was neutralized with KOH and centrifuged (13,000 g, 10 min). The amino acid containing supernatant was dried in a vacuum concentrator, analyzed using the PICO-TAG HPLC system (Waters Corporation, Milford, MA [32, 33]), and standardized to protein recovery.
Measurement of protein synthesis
Myotubes were serum starved for 2 h in α-MEM then transferred to α-MEM supplemented with [ 3 H]-L-phenylalanine (52.33 kBq/ml). Cells were incubated at 37°C with the appropriate stimuli, and the assay was terminated with three changes of isotonic saline. Cells were scraped into 10% trichloroacetic acid (w/v) and centrifuged (21,600 g, 5 min). The pelleted proteins were washed twice with isotonic saline and resuspended (50 mM NaOH/1% Triton X-100 [v/v]). Radioactivity associated with both the pellet and supernatant was determined and standardized to protein recovery. Background counts were determined by brief exposure of L6 cells to α-MEM/[
3 H]-Phe and validated using cycloheximide (5 µg/ml)-treated control cells.
Statistical analysis
Statistical and linear regression analyses were performed by GraphPad-Prism software. Unpaired t test or one-way ANOVA was performed followed by either the Newman-Keuls or Dunnett post-test. Data were considered statistically significant at P < 0.05. Uptake data were fitted to the following equations: (Fig. 1A) and (Fig. 1B) , where -ln(0.5/b) = t 1/2 .
RESULTS
Down-regulation of System A activity by ceramide
To determine whether ceramide accumulation affected System A transport in skeletal muscle, we incubated L6 myotubes with the cell-permeable ceramide derivative C 2 -ceramide for 2 h. Increasing concentrations of C 2 -ceramide induced a progressive decrease in System A activity (as assessed using radioactive Me-AIB, a specific System A substrate; Fig. 1A ) with an ED 50 of 19.0 µM C 2 -ceramide. This dose-response closely parallels our previously published data concerning the inhibition of insulin-stimulated glucose transport by ceramide (17) . We next determined the time course of ceramide action on System A activity (Fig. 1B) . Pretreatment of L6 cells with 100 µM C 2 -ceramide caused a rapid and time-dependent reduction in System A transport with t 1/2 = 37.1 min. This response is considerably more rapid than would be expected based on previous predictions of the t 1/2 of System A activity in cycloheximide-treated L6 myotubes (4-5 h; see ref 34).
To assess the impact of cellular ceramide treatment on the transport of nutritionally important amino acids, we determined the uptake rates of radiolabeled alanine (a good System A substrate) and leucine (a poor System A substrate) at concentrations approximating their physiological abundance (500 µM alanine and 100 µM leucine; Fig. 1C and 1D, respectively). Ceramide treatment significantly inhibited alanine transport, consistent with the marked inhibition of System A observed above, although the rate of leucine transport was not significantly affected by ceramide. In combination with the latter results, the demonstration that ceramide pretreatment did not affect the basal rate of 2-deoxyglucose transport ( Experiments were performed to address whether endogenous synthesis of ceramide may mimic the effects of C 2 -ceramide provision on System A activity. We have recently demonstrated that provision of the C 16 saturated fatty acid palmitic acid leads to an elevation in intracellular ceramide in L6 myotubes (35) , whereas palmitoleic acid, a C 16 ∆9 monounsaturated fatty acid, does not increase ceramide levels, although both compounds can be metabolized to diacylglycerol. L6 cells were incubated with palmitate or palmitoleate (at 0.75 mM, a concentration within the physiological range for plasma nonesterified fatty acids; 36) or with vehicle (2% BSA w/v) for 16 h, and then System A activity was assessed. Palmitate treatment led to a significant reduction in System A activity (vehicle 9.31±1.44 pmol/min/mg protein; palmitate 4.69±1.57 pmol/min/mg protein; P<0.05), whereas palmitoleate had no significant effect on System A activity (9.84±1.44 pmol/min/mg protein; P>0.05 vs. vehicle).
Ceramide reduces plasma membrane SNAT2 abundance
Regulated intracellular trafficking of SNAT2 has been implicated in the hormonal control of System A transport in L6 muscle cells (11), a cell line in which SNAT2 is the sole System A transporter expressed (data not shown and ref 29). To test whether subcellular transporter redistribution may underlie the inhibition of System A by ceramide, we isolated plasma membranes from L6 myotubes following pretreatment with 100 µM C 2 -ceramide for 2 h ( Fig.  2A) . Western blot analysis of the L6 plasma membrane fractions revealed that C 2 -ceramide significantly reduced the cell surface abundance of SNAT2 (by ~60%). In control experiments, the use of C 2 -dihydroceramide (an inactive ceramide derivative) failed to elicit an equivalent change in plasma membrane SNAT2 abundance ( Fig. 2A) . No significant changes in the total cellular abundance of SNAT2 were observed with any treatment, indicating that SNAT2 proteins were being internalized rather than broken down. To demonstrate that the subfractionation protocol was effective in isolating plasma membranes, the same membrane fractions were reprobed with an antibody directed against the α-subunit of the Na/K-ATPase, a plasma membrane marker (11, 17, 29) and actin. Ceramide caused a slight reduction in the cell surface expression of the Na/K-ATPase α-subunit; however, since this effect was mimicked by C 2 -dihydroceramide-a compound that does not affect System A activity (see below)-it seems unlikely that effects on the Na/K-ATPase contribute to the inhibition of System A by ceramide.
To allow comparison with the uptake data shown in Figure 1 , the dose-dependent effect of ceramide treatment upon SNAT2 localization was determined. L6 myotubes treated with incremental doses of C 2 -ceramide showed a corresponding decrease in plasma membrane SNAT2 abundance (Fig. 2B ).
Ceramide impairs the stimulation of System A transport activity by insulin
In muscle and adipose tissue, ceramide accumulation opposes the stimulation of glucose transport and glycogen synthesis by insulin (17) . The stimulation of System A activity is another well-documented insulin response in skeletal muscle (reviewed in ref 2) and, as such, experiments were performed to test whether ceramide affected the up-regulation of System A by insulin. As shown in Figure 3A , treatment of L6 cells for 30 min with 100 nM insulin led to an increase in System A activity of ~40%. Pretreatment of cells with 100 µM C 2 -ceramide for 2 h led to a reduction in basal System A activity (as shown previously in Fig. 1) , and, furthermore, the residual System A activity in cells pretreated with ceramide was insensitive to stimulation by insulin. C 2 -dihydroceramide, which in Figure 2 is shown not to affect the plasma membrane abundance of SNAT2, influenced neither basal nor insulin-stimulated amino acid transport. Since C 2 -dihydroceramide was without effect over System A, we propose that the inhibition of System A by C 2 -ceramide is a specific cellular response to ceramide signaling, rather than a direct effect of the lipid on the cell membrane.
Signaling mechanisms regulating System A transport
Ceramide has been shown to directly regulate numerous signaling pathways. Experiments were therefore performed to characterize the likely involvement of ceramide signaling in System A regulation.
To investigate whether a ceramide-activated protein phosphatase similar to that described by Cazzolli et al. (28) was involved in the regulation of amino acid transport, we incubated L6 cells with 250 nM okadaic acid (a concentration that inhibits protein phosphatase 2A enzymes). As shown in Figure 3A , such treatment did not alleviate the inhibition of either basal or insulinstimulated System A activity by C 2 -ceramide.
Previous work from our group has demonstrated that in L6 myotubes, the ceramide-induced resistance of glucose transport to insulin stimulation is due to a disruption in the insulin-induced recruitment and activation of protein kinase B (PKB). The hormonal activation of glucose transport after ceramide treatment is retained in cells expressing a constitutively active membrane-targeted PKB construct (mPKB) (17) . In agreement with previous results (31), System A activity is ~35% higher in mPKB-L6 cells (Fig. 3B) , although the net insulin response in these cells is similar to that observed in wild-type L6 myotubes. However, following ceramide treatment, System A activity in mPKB-L6 is suppressed to the same level as is observed in empty vector-transfected cells. Hence, although constitutive activation of PKB enhances basal System A activity, it does not counteract the inhibitory effect of ceramide on System A activity. This indicates that ceramide may act upon System A through a mechanism independent of that by which the lipid suppresses PKB signaling, implying that the ceramide-sensitive pathways regulating glucose transport (17) and System A amino acid transport may differ.
Several PKCs are targets of ceramide signaling (reviewed in ref 16); for example, PKCζ is activated (28, 37) and PKCε is inhibited (38) in response to ceramide. Our recent work has shown that ceramide signaling through PKCζ can be inhibited by low micromolar concentrations of Ro 31.8220, a bisindolylmaleimide derivative of staurosporine (37) . Ro 31.8220 neither inhibited nor mimicked the effect of ceramide on basal System A activity (Fig. 3C ), which suggests that the ceramide-induced inhibition of System A occurs independently of PKC signaling. Ro 31.8220 did impair the stimulation of System A by insulin, consistent with studies using staurosporine performed by Zorzano's group (39) . This implicates PKC, or PKC-related kinases, in the insulin-dependent regulation of System A.
Ceramide-induced depletion of intracellular amino acid content
The free amino acid pool of skeletal muscle is suggested to have a role in the initiation of catabolic and anabolic signaling in this tissue (reviewed in ref 40) . To assess whether the ceramide-induced internalization of SNAT2 had consequences for the cellular amino acid pool, we determined the intracellular amino acid composition of L6 myotubes by HPLC following ceramide treatment. L6 myotubes were incubated in α-MEM lacking ceramide or supplemented with two different concentrations of ceramide (10 µM and 100 µM) for 2 h. The cells were then harvested and the intracellular amino acid content determined (Table 1 ). This method allows the molar quantification of amino acids per milligram of cellular protein, but, since the internal concentrations of certain amino acids (e.g., glutamine, glutamate, aspartate) can be several orders of magnitude higher than those of certain other amino acids (e.g., leucine, isoleucine, tyrosine), the data in Table 1 are presented as the percentage of the initial amino acid content remaining following ceramide treatment.
As shown in Table 1 , a 2 h exposure of L6 cells to 100 µM ceramide elicited a general reduction in intracellular amino acid content (analysis omitting cysteine and lysine for technical reasons). This was most apparent for glutamine, glutamate, and aspartate (P<0.05), whereas any changes observed for other amino acids were not deemed to be statistically significant over the time period studied.
The three amino acids for which ceramide elicited a significant reduction constitute three of the most abundant amino acids within the cell, and ceramide therefore induces a significant diminution of the total intracellular amino acid pool size. A decrease in the mean amino acid content of L6 cells was observed with increasing ceramide treatment (control, 570±125 nmol/mg protein; 10 µM ceramide, 435±110 nmol/mg protein; 100 µM ceramide, 285±115 nmol/mg protein). Of the ceramide-induced reduction in intracellular amino acid concentrations, only 57.5% and 37.6% (10 and 100 µM, respectively) can be accounted for by the significant reductions seen in glutamine, glutamate, and aspartate levels under these conditions. The cumulative statistically insignificant effects of ceramide on amino acids other than those mentioned above account for the remainder of the ceramide-induced reduction in total amino acid content (values of 58.9 nmol/mg protein and 164.5 nmol/mg protein for 10 µM and 100 µM ceramide, respectively).
Ceramide inhibits amino acid-dependent cell signaling
The protein kinase mTOR (mammalian target of rapamycin) has been implicated in the control of protein synthesis (reviewed in refs [40] [41] [42] . mTOR is subject to tight regulatory control dependent upon hormonal (insulin) and nutritional (amino acids) inputs (40) (41) (42) (43) . Amino acid deprivation decreases mTOR signaling; however, the nature of the nutrient sensor(s) involved in this response is currently uncertain. Since ceramide reduces both System A activity and the intracellular concentration of a number of amino acids, we sought to define the effects of ceramide on the mTOR pathway.
As shown in Figure 4A , treatment of serum-deprived L6 cells with 100 µM ceramide led to a reduction in the phosphorylation of components of the mTOR signaling pathway. The ribosomal protein S6 and its upstream kinase S6K1 (both α and β splice-variants) were dephosphorylated in a time-dependent manner (lanes 1-5). These effects were similar to the inhibitory effects of rapamycin on S6 and S6K1 phosphorylation, consistent with a role for mTOR in ceramide signaling (data not shown). PKB has been implicated in the activation of mTOR signaling (reviewed in ref 44) , and given the inhibitory effect of ceramide on insulin-stimulated PKB activity (17) and the inhibition of amino acid transport by ceramide, the effects of ceramide on mTOR signaling in response to insulin and amino acids were studied. 3 and 7) . Similarly, the insulin-induced phosphorylation of TSC2 (at serine 939), a putative PKB substrate reported to inhibit mTOR signaling while in a dephosphorylated state (44) , is maintained in the presence of ceramide (albeit to a lower level than in the absence of the lipid; compare lanes 3 and 7). Resupplementation of amino acids (for 15 min) to cells that had been previously amino acid-deprived led to a robust rephosphorylation of ribosomal protein S6 (compare lanes 5 and 9), which was impaired by ceramide (compare lanes 6 and 10)
Ceramide inhibits protein synthesis in muscle cells
The reduction in System A activity, cellular amino acid levels, and mTOR signaling observed following ceramide treatment led us to speculate that ceramide may impair mRNA translation in L6 cells. To test this, we estimated protein synthesis by assessing the incorporation of a [ 3 H]-phenylalanine tracer into cellular protein (Fig. 5A ). The results demonstrate that, following a 4 h incubation, 100 µM ceramide significantly reduces (P<0.05) cellular protein synthesis by 33.5%. No significant change in the intracellular accumulation of the phenylalanine tracer was produced by ceramide treatment (Fig. 5B) .
DISCUSSION
In skeletal muscle, System A amino acid transport is regulated by a variety of influences. The results described herein implicate muscle ceramide as a novel regulator of transport function, protein synthesis, and amino acid levels. Our current model to explain the regulation of these aspects of muscle cell function by ceramide is presented in Figure 6 . In the basal state (Fig. 6A) , cell surface SNAT2 carriers transport extracellular amino acids to the intracellular pool, where they may be used for protein synthesis. The rate of protein synthesis is governed by a number of cellular controls, including signaling by the mTOR pathway-to which amino acid availability provides a positive influence (40) (41) (42) (43) (44) . Elevated ceramide levels stimulate the internalization of SNAT2 (Fig. 6B) , thus reducing System A activity at the cell surface, which is likely to contribute to the diminution of the intracellular amino acid pool. Ceramide reduces both protein synthesis and signaling by the mTOR pathway, and we propose that there is a causal link between the reduced intracellular amino acid availability and these phenomena. Nonetheless, the possibility exists that ceramide may inhibit mTOR signaling either downstream or independently of amino acid sensing pathways (as indicated by the dotted line in Fig. 6B ). In the presence of insulin (Fig. 6C) , both System A and glucose transport are stimulated by mechanisms sensitive to ceramide. However, distinct pathways are implicated since the effect of ceramide on glucose transport (17), but not System A (this report), can be bypassed following the consititutive activation of PKB.
Muscle ceramide as a catabolic influence
Multiple disparate effectors influence muscle ceramide levels. For example, elevated muscle ceramide levels have been documented following prolonged fasting (21) and muscle denervation (22) and are observed in obese Zucker rats (22) . Furthermore, increased ceramide content has recently been demonstrated in the muscle of obese insulin-resistant human subjects (45) . Ceramide is reported to function as a second messenger in cytokine signaling (reviewed in ref 24), and ex vivo studies suggest ceramide may contribute to insulin resistance induced by saturated fat intake (reviewed in ref 16 ). Many of these stimuli/conditions are associated with muscle atrophy and with the insulin resistance or inhibition of muscle AIB transport (46) (47) (48) (49) (50) , although a role for ceramide in these effects has not been explored. Conversely, rats subjected to exercise have reduced muscle ceramide content (23) and a potentiated response of AIB transport to supraphysiological insulin concentrations (51) . Given the inhibitory effects of ceramide on protein synthesis and amino acid transport observed in the current study, it is conceivable that ceramide has a significant catabolic function in skeletal muscle in vivo. Pharmacological (e.g., use of sphingomyelinase/ceramide synthase inhibitors) and nutritional (e.g., manipulation of dietary fat content) interventions that reduce muscle ceramide levels may therefore have potential as beneficial therapies in the treatment of catabolic muscle-wasting conditions.
Control of the intracellular amino acid pool
Amino acids are potent signaling molecules in skeletal muscle (and other tissues) with regulatory capacity over a variety of cellular processes, including protein synthesis, proteolysis, glycogen synthesis, amino acid transport, and gene expression (reviewed in refs 40-44 and 52). With respect to protein synthesis, the regulation exerted by amino acids is not entirely a substrate limitation effect but rather may be due to the existence of specific signaling mechanisms (notably the mTOR pathway) that stimulate the translational machinery in response to increased amino acid availability. Both intracellular and extracellular amino acid sensors have been implicated in amino acid-dependent mTOR signaling (53) (54) (55) . Where intracellular sensors have a predominant role, cellular stimuli that diminish the intracellular amino acid pool without reducing extracellular availability (such as ceramide) would be anticipated to mimic signaling due to amino acid deprivation. This is precisely the effect that we observe following ceramide treatment, strengthening the argument that L6 cells have an intracellular amino acid sensor. Nevertheless, the possibility that ceramide inhibits amino acid signaling at a postsensor locus cannot be discounted at present. Our data also complement those of Bevington et al. (56) , who demonstrated that proteolysis was enhanced in L6 cells following System A inhibition by the competitive inhibitor Me-AIB. In both studies, System A inhibition (by ceramide or Me-AIB) reduced the intracellular levels of both System A and non-System A amino acids. Amino acids are transported by a number of distinct systems, many of which (e.g., Systems L/ASC/asc/x -c ) function as amino acid exchangers, which are less likely to contribute to the total amino acid distribution ratio than unidirectional transporters such as System A. Expansion and contraction of the intracellular amino acid pool may, therefore, be determined by the activity of a subset of amino acid transporters, of which System A is likely to be an important member. Such a role may help to account for the high degree of regulation to which System A is subject in muscle (and other tissues) (2), compared with System L, for example.
Control of System A by intracellular signaling mechanisms
The molecular mechanisms of System A regulation presently defined include transcriptional and posttranslational events, of which subcellular redistribution may account for SNAT2 activation by insulin (in muscle; 11) and partial hepatectomy (in liver; 13). The evidence presented here showing a reduction in plasma membrane SNAT2 upon ceramide treatment provides the first demonstration of controlled System A down-regulation through translocation events. The signaling pathways and molecular machinery involved in the regulation of SNAT2 are poorly defined in contrast with other highly regulated transporters, such as GLUT4. Stimulation of glucose and System A amino acid transport by insulin shares certain characteristics (e.g., wortmannin sensitivity/rapamycin and PD098059 insensitivity), although significant differences between the two raise the possibility that distinct pathways operate to control the two processes. This notion is supported by several findings: 1) a constitutively active PKB construct stimulates both System A and glucose transport in L6 cells (31); however, this construct maintains glucose transport (17), but not System A (this report), at an elevated level of activity following ceramide treatment; 2) cytochalasin D, a drug that disrupts actin filaments, blocks the insulin-dependent activation of PKB (57) and glucose transport (58) in L6 myotubes, but not System A (11); and 3) phorbol esters mimic insulin signaling to muscle glucose transport, while attenuating the insulin responsiveness of System A (59). In L6 cells, insulin-induced System A activity is inhibited by the PKC inhibitor Ro 31.8220. This result is consistent with an earlier report (39) that several PKC inhibitors prevent the activation of muscle System A by insulin and is intriguing since PKC enzymes are known to be dysregulated in lipid-induced insulin resistance (reviewed in ref 16) , although note that Ro 31.8220 and other bisindolylmaleimides have been shown to inhibit a number of kinases, including, but not restricted to, the PKC isozymes (60) .
A role for sphingolipids in the regulation of amino acid transporters (namely TAT1 and TAT2, transporters from a structurally distinct protein superfamily from SNAT2) has been demonstrated in the yeast Saccharomyces cerevisiae (61, 62) . Chung et al. demonstrated, through the use of yeast mutants, that phytosphingosine is a key player in the inhibition of both growth and amino acid transport (61) . Therefore, the possibility exists that intracellular metabolism may be a prerequisite for the biological activities of C 2 -ceramide presently documented. Indeed, in mammalian cells, ceramide can be metabolized to numerous lipid species (including sphingosine, glucosylceramides, 1-O-acylceramides, ceramide-1-phosphate, and sphingomyelins), and inhibitors are available for a subset of the metabolic enzymes involved in ceramide metabolism (reviewed in ref 63). In de novo phytoceramide synthesis, phytosphingosine is metabolically equivalent to dihydroceramide in mammalian cells (being the biosynthetic precursor to phytoceramide; 61), although phytosphingosine is structurally most closely related to sphingosine. In the current study, C 2 -dihydroceramide did not impair System A transport, suggesting that unlike in yeast, muscle amino acid transport may be controlled by ceramide or a downstream product of ceramide metabolism.
Coregulation of System A and mTOR signaling
Our data suggest a level of concordance between the regulation of mTOR signaling and System A activity in L6 muscle cells, since ceramide inhibits mTOR and System A, whereas insulin stimulates the two phenomena. With respect to muscle insulin responses, this makes a great deal of sense: insulin stimulates protein synthesis and inhibits protein degradation (processes influenced by mTOR signaling [40, 64] ) and would be anticipated to reduce the intracellular amino acid pool. However, through stimulation of amino acid transporters, such as System A and System N m , this depletion may be prevented and the amino acid pool may actually increase. Furthermore, since amino acid sensors have been implicated in the regulation of mTOR signaling, the stimulation of transport by insulin may increase delivery of amino acids to these sensors and thus contribute to signal amplification through mTOR. Evidence suggestive of coregulation between mTOR and amino acid transport is seen in work showing that both System A activity (reviewed in ref 65) and mTOR signaling (reviewed in ref 44 ) increase in transformed cell lines and during cell cycle progression. Cell growth depends on an increase in cell volume, and amino acid transport has been implicated in cell volume regulation (reviewed in refs 42, 43, and 65). mTOR activation has been shown to stimulate amino acid transport (66, 67) , and this may contribute to cell volume and hence growth and/or division (66) . Conversely, cell shrinkage in response to amino acid deprivation has been suggested as an inhibitory effector of mTOR signaling (42) , and cell swelling in response to hypotonicity stimulates mTOR-dependent glycogen synthesis (68) . Nevertheless, in the current system, the inhibition of mTOR by ceramide is unlikely to be directly responsible for System A inhibition, because rapamycin does not reduce basal System A activity in L6 myotubes (67) .
Despite the inhibition of basal mTOR signaling and insulin-stimulated PKB phosphorylation by ceramide, the insulin responsiveness of core elements of the mTOR pathway (TSC2/S6K1/S6) was at least partly maintained. This was a surprising finding as many recent papers (reviewed in ref 44) have demonstrated that PKB phosphorylates mTOR and the tumor suppressor TSC2 (a regulator of mTOR). In our system, insulin-stimulated PKB signaling was inhibited by ceramide, but TSC2 phosphorylation (at serine 939) was maintained, albeit at a lower level than in the absence of ceramide. These results indicate the involvement of both PKB-dependent and PKBindependent pathways in the phosphorylation of TSC2, and indeed Tee et al. have recently demonstrated PKB-independent phosphorylation of TSC2 in response to phorbol esters (69) . The observation that insulin-stimulated S6 phosphorylation was partially sensitive to inhibition by ceramide (Fig. 4B) implies that the lipid may influence the mTOR signaling pathway at multiple levels.
In summary, our data demonstrate a previously unanticipated effect of a lipid metabolite (ceramide) on amino acid transport and signaling, which potentially may be of great importance in whole body protein and energy metabolism. The regulation of hormonal signaling by lipids and amino acids may have important consequences for protein balance in skeletal muscle and the insulin sensitivity of this tissue. Manipulation of lipid metabolism in skeletal muscle, therefore, may be of benefit in the treatment of diabetes and muscle wasting. concentration of C 2 -ceramide or 100 µM C 2 -dihydroceramide (C 2 -DH-Ceramide) for 2 h. Following isolation, plasma membrane-enriched or total L6 membranes were subject to SDS-PAGE and immunoblotting for SNAT2, the Na/K-ATPase α-subunit, or actin. 
